GE Healthcare/GlaxoSmithKline team on cancer test improvements; Myriad Genetics reports promising companion Dx results;

> GE Healthcare ($GE) affiliate Clarient Diagnostic Services will work with GlaxoSmithKline ($GSK) to develop better laboratory and data analytics testing for cancer. Release

> Myriad Genetics ($MYGN) said its BRACAnalysis CDx companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations in 44% of women with ovarian cancer. Release

> A European regulatory committee is recommending marketing authorization for Navidea Biopharmaceuticals' ($NAV) Lymphoseek imaging agent to help diagnose breast cancer, melanoma, or head and neck cancers. Release

> AltheaDx won approval from the New York Department of Public Health for its suite of pharmacogenetic tests and can now sell them across the country. Story (sub. req.)

> Frost & Sullivan gave Roche's ($RHHBY) Ventana Medical Systems a shout-out for having a diverse line of products and services for the cancer diagnostics market. Release

> Foundation Medicine ($FMI), Illumina ($ILMN) and Roche ($RHHBY) are among the companies that participated in the third annual "Blueprint for Drug/Diagnostic Co-development" forum. Item

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.